Parameter | Hazard ratio (95% CI) |
---|---|
Linear time coefficient DAS28 trajectory latent class 1 | 1.04 (1.02–1.06) |
Quadratic time coefficient DAS28 trajectory latent class 1 | 1.66 (0.42–6.55) |
Linear time coefficient DAS28 trajectory latent class 2 | 1.14 (1.08–1.20) |
Quadratic time coefficient DAS28 trajectory latent class 2 | 4.52 (3.83–5.33) |
Time to reach stable low disease activity (weeks)a | 0.97 (0.96–0.98) |
DAS28 at baseline | 1.18 (0.90–1.54) |
Prescribed dose (% of standard dose) at baseline | 1.21 (0.88–1.67) |
SJ increase at baseline (yes/no)b | 1.72 (0.94–3.17) |
TJ increase at baseline (yes/no) b | 2.07 (1.13–3.81) |
Disease duration (years) at start of bDMARD | 1.02 (0.99–1.05) |
Seropositivity (RF and/or ACPA) | 2.51 (1.39–4.53) |
bDMARD TNFi type (yes/no) | 0.90 (0.54–1.49) |
bDMARD dose ≤50% of full registered dose (time-varying variable) | 2.21 (1.73–2.82) |